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Abstract
Background Nephrotic syndrome (NS) presenting early in life
is caused by heterogeneous glomerular diseases. We retro-
spectively evaluated whether histological diagnosis in chil-
dren presenting with NS in the first year of life predicts
remission or progression to end-stage kidney disease
(ESKD).
Methods This is a single centre retrospective review of all
children diagnosed with NS before one year of age between
1990 and 2009. All subjects had a renal biopsy, which was
independently blindly reviewed by a single renal pathologist
for the purpose of this study.
Results Forty-nine children (25 female) who presented at 0.1–
11.6 (median 1.6) months were included with 31 presenting
within the first three months of life. Histopathological review
diagnostic categories were; 13 Mesangial proliferative glo-
merulopathy (MesGN), 12 Focal and segmental
glomerulosclerosis (FSGS), 11 Finnish type changes, eight
Diffuse Mesangial Sclerosis (DMS), three Minimal change
disease (MCD) and one each of Dense Deposit Disease
(DDD) and Membranous nephropathy. Two children died
from haemorrhagic complications of the biopsy. Eight chil-
dren achieved remission (four MesGN, one Finnish type
changes, one FSGS, one MCD and one membranous) with
patient and renal survival of 73 % and 43 %, respectively, at
follow-up duration of 5–222 (median 73) months (with five
lost to follow-up). All children with Finnish-type histopatho-
logical changes presented within five months of age. Due to
the historical nature of the cohort, genetic testing was only
available for 14 children, nine of whom had an identifiable
genetic basis (seven NPHS1, one PLCE1 and one ITGA3)
with none of these nine children achieving remission. All of
them had presented within four months of age and required
renal replacement therapy, and two died.
Conclusions Histopathological findings are varied in children
presenting with NS early in life. Whilst groups of histological
patterns of disease are associated with differing outcomes,
accurate prediction of disease course in a specific case is
difficult and more widespread genetic testing may improve
the understanding of this group of diseases and their optimal
management
Keywords Congenital nephrotic syndrome . Infantile
nephrotic syndrome . Histopathology . Genetics . Outcome
Introduction
Nephrotic syndrome (NS) which appears early in life provides
a diagnostic and management challenge to pediatric
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nephrologists[1]. It is caused by heterogeneous glomerular
diseases, and the diagnosis is based on clinical, laboratory,
and histological criteria[2]. Congenital nephrotic syndrome
(CNS) is a term used for NS presenting within the first three
months of age while infantile nephrotic syndrome (INS) is
used for NS presenting between three and 12 months of age.
CNS and INS are commonly associated with Finnish type
nephropathy [3] or Diffuse Mesangial Sclerosis (DMS) on
histological examination[4, 5]. However, other glomerular
pathologies have also been reported such as focal and seg-
mental glomerulosclerosis (FSGS) and minimal change dis-
ease (MCD)[6, 7].
Early onset NS is usually caused by a genetic defect in a
major podocyte slit diaphragm protein, Nephrin (NPHS1)[8],
or less commonly by mutations in WT1[9], PLCE1 [10],
LAMB2 [11] or NPHS2 [12]. Non-genetic causes include
infections such as congenital toxoplasmosis [13], cytomega-
lovirus infection [14], or congenital syphilis [15]. Hinkes et al.
[12] reported that two-thirds of nephrotic syndrome manifest-
ing in the first year of life can be explained by mutations in
four genes (NPHS1, NPHS2, WT1, or LAMB2), and these
children with identified genetic causes should not be treated
with corticosteroids, as they are steroid-resistant. In addition,
there are children with congenital NS who spontaneously
improve: some of these patients may have anti-glomerular
antibodies transferred from the mother [16], although in many
children, the reason for developing NS is unexplained[17].
A renal biopsy in children under 12 months of age with NS
can, however, be technically difficult to perform, with poten-
tially serious complications, especially in small oedematous
children. The clinical utility of the biopsy result with respect to
prognosis and management is unclear in the era of increased
genetic testing. In the present study, we, therefore, retrospec-
tively investigated the histological findings and clinical course
of children who presented within one year of age with NS and
required admission to the pediatric nephrology unit at Great
Ormond Street Hospital for Children NHS Foundation Trust
(GOSH) over twenty years between 1990 and 2009, and in
whom a renal biopsy was performed. Ethical approval was
obtained for this study from the University College London
Institute of Child Health and Great Ormond Street Hospital for
Children NHS Foundation Trust Research Ethics Committee.
Patients and methods
Inclusion criteria were children who presented within the first
year of life with nephrotic syndrome who had a histological
diagnosis obtained by renal biopsy between January 1990 and
December 2009. The clinical diagnosis of NS was made on
the basis of nephrotic range proteinuria (urine albumin/
creat inine rat io (UA:UC) above 200 mg/mmol) ,
hypoalbuminaemia (<25 g/l) and oedema. Clinical
management over the years before genetic testing was avail-
able usually included a renal biopsy in patients with CNS or
INS unless clinical management with early nephrectomy was
planned. However, this clinical practice was modified with
priority given to genetic studies in recent years.
Clinical, laboratory, and histological data were collected
from the medical notes of the patients, including age, renal
function, and quantification of albuminuria at onset of the
disease and at the time of renal biopsy. Data was recorded
on family history (including parental consanguinity), antenatal
history, birth weight, treatment [including immunosuppres-
sive agents, angiotensin converting enzyme inhibitors
(ACEi) and/or angiotensin receptor blockers (ARB)], clinical
course [including remission of NS, unilateral or bilateral na-
tive nephrectomies, or requirement for end-stage kidney dis-
ease (ESKD) management with dialysis and/or transplanta-
tion] and long-term follow-up. Extra-renal manifestations
(neurological, ophthalmological, hepatic, and gastro-
intestinal involvement) were evaluated from the notes.
All but six percutaneous renal biopsies were performed at
GOSH under ultrasound guidance and examined by light
microscopy, immunohistochemistry and electron microscopy.
The other children were referred with slides of renal biopsies,
which were performed at other institutions. All renal histology
was re-evaluated by a single pediatric renal pathologist (NS)
for the purpose of this study who was blinded to the clinical
outcomes of the patients. In addition, the histopathological
findings of 13 children who had nephrectomies (ten bilateral




Forty-nine children (25 female) from 48 different families
were included in the study. All had onset of NS within the
first year of life with renal histology obtained. The age at
presentation with NS was 0.1–11.6 (median 1.6) months, with
31 presenting within the first three months. Renal function
varied at presentation, with plasma creatinine of 4–160 (me-
dian 35) μmol/l. There was a high rate of consanguinity, with
15 parents being first cousins or second cousins and seven
children had affected siblings with CNS (Table 1).
Histological findings
Renal histology was obtained at 1–17 (median 6) months, of
which 35 had a percutaneous renal biopsy only; one had
nephrectomy only, and 13 had both. The histological catego-
ries of diagnoses were as follows (based on published mor-
phological criteria as available in standard texts): 13
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Mesangial proliferative glomerulonephritis (MesGN), 12
Focal segmental glomerulosclerosis (FSGS), 11 Finnish
nephropathy type changes, eight Diffuse Mesangial Sclero-
sis (DMS), three Minimal change disease (MCD) and one
each for Dense Deposit Disease (DDD) and Membranous
nephropathy. Histological examination was considered ade-
quate in the majority of samples with 4–106 (median 30)
glomeruli per biopsy and less than five and ten glomeruli
in one and six biopsies, respectively (Table 1).
Long-term outcome
Patient and renal survival was 73 % (32 children) and 43 %
(19 children), respectively, at follow-up duration of 5–222
(median 73) months with five lost to follow-up (follow-up
less than three months duration; three CNS and two INS).
Patient survival for CNS and INS was 64 % (18 children) and
88 % (14 children), respectively. Renal survival for CNS and
INS was 29 % (eight children; four MesGN, two FSGS and
two Finnish) and 69% (11 children; five DMS, five FSGS and
one Finnish), respectively. Two children died due to
haemorrhagic complications of the renal biopsy itself.
At the last follow-up at 5–222 (median 73) months; eight
children were in remission (six complete remission and two
partial remission), seven persistent NS, 14 were transplanted
(three had been re-transplanted and six had functioning renal
allografts), ten receiving dialysis, one with chronic kidney
disease, with 12 mortalities, and five lost to follow-up. Five
of those who died received renal replacement therapy: three
received dialysis; one received both dialysis and transplanta-
tion, and one child received a pre-emptive renal transplant.
The underlying cause of death was infection (peritonitis or
sepsis in four children), haemorrhagic complications of renal
biopsy (N=2), intracranial haemorrhage associated with hy-
pertension and anticoagulation therapy (N=1), gastrointestinal
haemorrhage (N=1). Details of the underlying cause were not
available in four children.
Histology-associated outcome
Finnish At last follow-up of the 11 patients with Finnish-type
histological changes at 14–79 (median 44) months, seven
children were alive, three deceased and one lost to follow-
up. Four had undergone nephrectomies (three bilateral and
one unilateral), five required dialysis at 2–11 (median 9)
months of age. Four of those dialysed received a subsequent
renal transplantation. One child (with Finnish-type histologi-
cal features on needle biopsy) went into spontaneous remis-
sion at seven months of age, although genetic testing was not
performed. On the last follow-up at four years of age, he
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MesGN Thirteen children had a histopathological diagnosis
of MesGN. At the last follow-up ten children were alive, two
had died and one lost to follow-up, with three children achiev-
ing remission. Four children required dialysis, and two of
these subsequently received a renal transplant (one of whom
was pre-emptively transplanted). Two children remained with
persistent NS.
FSGS Of the 12 patients with FSGS, nine were alive at 5–216
(median 26) months, two of whom achieved remission, five
required dialysis 3–147 (median 46) and three of those re-
ceived a renal transplant (Table 2).
DMS For the eight patients with DMS, four were alive at the
last follow-up at 19–195 (median 55) months, while four had
died at 1–16 (median 6) months and one patient was lost to
follow-up. Three children required dialysis at 7, 14, and
98 months of age. Two of those dialysed had subsequent renal
transplantation, and one of them had nephrectomy at the age
of 17 months of age (Table 2).
MCD Two children with MCDwere alive at 118–222 months
follow-up. One achieved remission; one had persistent NS,
while the third child required dialysis (at 12 months of age)
followed by transplantation at 35 months of age, which was
complicated by gastrointestinal haemorrhage; he subsequently
died (Table 2). The child who achieved remission was treated
with prednisolone and cyclophosphamide.
The case summaries of two children with an uncommon
histological diagnosis for this young age are described as
follows:
1. Dense Deposit Disease: a three-month-old girl presented
with a clinical nephritic-nephrotic syndrome,
hypocomplemenaemia (low C3), and acute kidney injury.
The biopsy showed diffusely abnormal glomeruli, with
80 % showing cellular or fibrocellular crescents and
MPGN morphological pattern. There was strong staining
with C3 along glomerular capillary walls and in globules
in the mesangium. Electron microscopy confirmed dense
deposit disease. She was treated with plasma exchange
and cyclophosphamide, with a progressive worsening of
renal function (plasma creatinine of 440 μmol/l). She was
dialysed and eventually transplanted without recurrence
of DDD in her renal transplant.
2. Membranous nephropathy: an 11 month-old-boy, with a
family history of membranous nephropathy (two uncles,
who presented at three and ten years of age, and a great-
uncle, who was diagnosed at 67 years of age) developed
steroid-resistant NS with hypertension and microscopic
haematuria [18]. His renal biopsy showed 47 diffusely
abnormal glomeruli, with segmental mesangial expansion
and marked thickening of the glomerular capillary walls.
Immunohistochemical staining revealed diffuse capillary
loop granular deposition of IgG, C1q and C3 and electron
microscopy confirmed membranous nephropathy. He was
commenced on mycophenolate mofetil (MMF), ACE
inhibitors, and ARB with a slow but persistent improve-
ment. At the age of ten years, he has had two prolonged
relapses, which eventually resolved with increased immu-
nosuppression, and he has normal renal function.
Immunouppression
Corticosteroids were used in seven children (Table 1) and
other immunsuppressive agents in three children. As detailed
above, one child with MCD and the child with DDD received
a course of oral cyclophosphamide, while the child with
membranous nephropathy was treated with MMF.
Nephrectomies
Thirteen children had nephrectomies following renal biopsies
(ten bilateral and three unilateral) performed at 2–147 (median
14) months. The result of the histological examination of the
Table 2 Outcome according to histology. All transplants were preceded by dialysis apart from one child with Mesangioproliferative histology who
received pre-emptive transplantation
n Remission Dialysis Renal transplantation Mortality rate Persistent NS Lost to follow-up Follow-up (months) (range)
MesGN 13 3 (23 %) 4 (31 %) 3 (8 %) 2 (15 %) 2 (15 %) 1 (8 %) 155(51-180)
FSGS 12 2 (17 %) 6(50 %) 3 (25 %) 2 (17 %) 2 (17 %) 1 (8 %) 26 (5-216)
Finnish 11 1(9 %) 5 (55.5 %) 4 (44 %) 3 (27 %) 1 (9 %) 2 (18 %) 44 (14-79)
DMS 8 0 (0 %) 3 (37.5 %) 2 (25 %) 4 (50 %) 1 (13 %) 1 (13 %) 55 (19-195)
MCD 3 1 (33 %) 1 (33.3 %) 1 (33 %) 1 (33 %) 1 (33 %) 0 (0 %) 192(118-222)
Other 2 1 (50 %) 1 (50 %) 1 (50 %) 0 (0 %) 0 (0 %) 0 (0 %) 44-48
Total 49 8 (16 %) 20 (41 %) 14 (29 %) 12 (24 %) 7 (14 %) 5 (10 %) 73 (5-222)
MesGN mesangial proliferative glomerulopathy, FSGS focal segmental glomerulosclerosis, DMS diffuse mesangial sclerosis, MCD minimal change
disease, NS nephrotic syndrome
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resected kidneys showed a similar histological diagnosis in
eight patients (seven with Finnish type changes and one with
DMS), while four cases demonstrated extensive changes of
ESKD with no further specific comment possible (one ne-
phrectomy specimen was not available for re-analysis). The
clinical indication for performing nephrectomies prior to
ESKD management was severe nephrotic syndrome in order
to minimise protein losses, reduce the risk of thrombosis, and
enable an early diagnosis of potential recurrence of NS [19].
Dialysis (mainly peritoneal dialysis) was performed in 13
nephrectomised children and in seven other children.
One patient had two renal biopsies; the initial biopsy at four
months of age suggested Finnish type changes, and the second
biopsy two months later showed similarly dilated tubules with
additional focal glomerulosclerosis without any mutation de-
tected on his genetic studies. He died at 8 months of age
because of sepsis, thromboembolism, gastrointestinal haem-
orrhage, and chronic kidney disease.
Extra-renal manifestations
In addition to clinical NS, ten children had major gastro-
intestinal disorders; seven had neurological complications,
and five had congenital heart disease. Non-infectious chronic
diarrhoea was the key symptom in six of the ten cases with
gastro-intestinal disorders, with severe weight loss and the
temporary need for total parenteral nutrition in two patients.
These children underwent intestinal biopsies, which showed
normal mucosa in three cases and moderate partial villous
atrophy in the other three cases, one of which had an increase
of inflammatory cell density with some eosinophils. The other
gastro-intestinal complications were relapsing pancreatitis in
two patients and hepatomegaly in two patients (with liver
biopsies revealing a centrilobular hepatocyte necrosis in one
case and normal in the other case). Neurologic disorders were
mainly represented by severe developmental delay in seven
children associated with microcephaly in three cases and
seizures in four children. One child had hydrocephalus, which
required ventriculoperitoneal shunt insertion. Two patients
had mild dysmorphic features which did not fit with an iden-
tifiable syndrome; one of them had cloudy cornea. Congenital
heart disease was observed in two children with Finnish-type
histology (one had pulmonary stenosis and one had patent
ductus arteriosus), while one child with MCD had an atrial
septal defect.
Genetic studies
Genetic results were available for 14 children only due to the
historical nature of this cohort, with nine having causative
mutations identified (Table 3). All of those with identified
causative mutations presented before four months of age and
did not achieve remission. Six required renal replacement
therapy (RRT), one died, and one was lost to follow-up. In
only two children was a heterozygote NPHS1 mutation de-
tected (c.1868G>T; p.C623F with Finnish-type histological
Table 3 Causative mutations identified
Pathology Age at presentation
(months)
Mutation found Age at biopsy
(months)
Outcome
FSGS 0.1 NPHS1: c.3478C>T; p.Arg1160* (Homozygous) 16 Nephrectomy and Pd at 46 months
and transplantation at 64 month
Finnish 0.1 NPHS1: c.1758-8_1785del deletion of 36 bp
including obligate splice site (Homozygous)
plus NPHS2: c.Arg229Gln (h)
7 Nephrectomy at 11 months and t
ransplantation at 14 months
MesGN 0.3 NPHS1: c.1868G>T; p.C623F and
c.2335-1G>A (compound heterozygous)
1 Nephrectomy and PD at 4,5 years and
transplantation and transplantation
at 5.5 years of age
FSGS-MCD 0.3 PLCE1: c.961C>T; p.Arg321* (Homozygous) 4 PD at 2 years and transplantation at
3 years of age
Finnish 1 NPHS1: c.2227C>T; p.Arg743Cys and
c.3442C>T; p.Gln1148* (compound heterozgous)
nephrectomy at
6 months
Haemodialysis at 6 years and
transplantation at 6.5 years of age
Finnish 1.6 NPHS1: c.1099C>T; p.Arg367Cys (Homozygous) 3 Nephrectomy and dialysis at 7 months
and transplantation at 24 months
Finnish 1.9 NPHS1: c.2227C>T; p.Arg743Cys and
c.3481+1G>T (compound heterozygous)
7 Dialysis at 9 months of age
FSGS 4.3 ITGA3: c.1883G>C, p.Arg628Pro (Homozygous) 5 Died after commencing dialysis
MCD-FSGS 4 NPHS1 c.614_621delinsTT p.Thr205_
Arg207delinsIle and c.2928G>T, p.Arg976Ser
(compound heterozygous)
5 Nephrectomy, dialysis followed by
transplantation at 12 years of age
MesGN mesangial proliferative glomerulopathy, FSGS focal segmental glomerulosclerosis, DMS diffuse mesangial sclerosis, MCD minimal change
disease
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changes and c.1223G>A;p.R408Q with DMS type histology).
Both of them required dialysis and transplantation. It is possible
that the second mutation was not identified. The child with a
homozygous mutation in ITGA3 has been reported previously
[20]. The child with the homozygous PLCE1mutation also had
an atrial septal defect and right atrial thrombectomy. She had
chronic recurrent pancreatitis and developed new onset of
diabetes after transplantation (NODAT) requiring insulin. The
histological diagnosis and outcome of the five children who
had genetic testing performed but without identified causative
mutations are summarized in Table 4. All patients with causa-
tive NPHS1 mutations had at least one severe (nonsense or
splice site) mutation, except for the patient with the homozy-
gous R367C mutation, which has been previously shown to
cause aberrant trafficking of nephrin [21].
Discussion
The findings of the present study demonstrate that NS pre-
senting in the first year of life is caused by heterogeneous
glomerular diseases and that the histological diagnosis, whilst
providing prognostic information, does not predict outcome in
all cases. Genetic results were available only in a minority of
patients, but none of the children with identified causative
mutations achieved remission and all required RRT. Of
course, genetic testing in such a retrospective study is highly
likely to have included preselected cases in whom biopsy
findings would suggest a high yield of positive mutations.
All children with Finnish-type histopathological changes
presented before five months of age. Similarly, the majority of
children with DMS presented early within the first six months
of life. However, some children with FSGS, MesGN, MCD,
and DDD also presented early, even within the first three
months of age as also described by others [6, 7].
Histopathological findings cannot predict outcome with
certainty since disease course varies among aetiological
group. For example, one child with apparent Finnish-type
histological features on initial needle biopsy, achieved remis-
sion. Remission in children with primary CNS associated with
Finnish histopathology, DMS [15] or other patterns of histo-
pathological changes is uncommon but has been reported
previously [17]. This is different from the subgroup of infan-
tile NS secondary to infections which carries a good prognosis
with improvement as the underlying disease is treated [22].
Around one sixth of the children had a positive family history
of an affected sibling and there was history of parental consan-
guinity in 31 %. Sixty-four percent of tested children had an
identifiable genetic cause with homozygous or compound het-
erozygous mutations in NPHS1 (six patients), PLCE1 (one
patient) or ITGA3 (one patient). All those presented early and
failed to achieve remission. This is similar to previous studies
where mutations were found to be associated with an earlier
onset of disease and worse renal outcomes [7, 23]. However,
milder cases were also reported to be associated with either two
NPHS1 mutations in the cytoplasmic tail or two missense
mutations in the extracellular domain, including at least one that
preserved structure and function [7]. One child with a histolog-
ical diagnosis of FSGS had underlying PLCE1 mutations. Al-
though PLCE1 has been primarily associated with DMS it has
been previously described to be mutated in a non-negligible
proportion of FSGS cases without NPHS2 mutations [24].
None of the children with mutations responded to treatment
or achieved remission, which is in keeping with the recom-
mendation that most patients with genetic SRNS do not ben-
efit from immunosuppression with rapid progression to ESKD
[25, 26].
Six children suffered from considerable diarrhoea, which
has been previously described in infantile nephrotic syndrome
and may be explained by infection [2] or as a result of losing
plasma proteins in the intestine due to intestinal oedema [27].
Two subjects suffered from chronic relapsing pancreatitis with
one death associated with this complication. Acute pancreati-
tis can be related to renal venous and inferior vena cava
thrombosis, which is a known complication of NS [28]. We
observed developmental delay in seven children, which was
associated with microcephaly in three of them. However, none
Table 4 Outcome and findings in children without identified causative mutations
Pathology Age at presentation(months) Mutation found Age at biopsy (months) Outcome
Finish 0.3 Hetrozygous NPHS1 variant
(c.320C>T;p.Ala107Val)
7 Dialysis at 10 months of age
FSGS 1 None 2 Dilaysis at 3 months of gae and
died from sepsis at 9 months of age
MesGN 5.5 None 5 Remission
DMS 8.6 Heterozygote NPHS1 variant
(c.1223G>A;p.Arg408Gln)
10 Dialysis at 15 months of age
Membranous 11.6 None 12 Remssion
MesGN mesangial proliferative glomerulopathy, FSGS focal segmental glomerulosclerosis, DMS diffuse mesangial sclerosis, MCD minimal change
disease
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of them had other features of Galloway-Mowat syndrome
such as hypotonia and hiatus hernia [29]. This may be related
to the often prolonged hospitalizations, complicated by septic
episodes and multiple intensive care stays and/or the severe
protein loss with failure-to-thrive.
We had one girl who presented with CNS with a renal biopsy
confirming DDD and resulting in rapid progression to ESKD.
DDD has been reported as a cause of SRNS in young children
[30, 31] and in infants [32] but not as a cause of CNS. We had
one patient who presented at one year of age with NS and biopsy
revealed membranous histopathology. He achieved remission
which is similar to previous reports of membranous nephropathy
as a rare cause of NS in children with benign outcome [33].
Historically, prior to the availability of genetic testing,
percutaneous renal biopsies were performed to understand
the histopathology and guide treatment with prognostic infor-
mation. However, in our cohort, two children died as a result
of haemorrhagic complications from the renal biopsy itself.
Unfortunately, there were small numbers of patients in some
of the subgroups (such as MCD) to be able to comment on
overall prognosis, but unsurprisingly, only one of the Finnish
type patients went into remission, and none of the DMS
patients, who had the highest mortality rate of 50 %.
Children with identified causative mutations generally pre-
sented earlier and had poor renal outcome. The time taken to
obtain genetic testing results is decreasing with improving
technology. The availability of genetic testing varies from
centre to centre and country to country. More importantly,
reimbursement for these tests is highly variable, so that in
some cases, testing can only be performed by research labs
with undefined time spans for the availability of results. Thus,
in some centres, it may not be possible to obtain a test or wait
for the result within a time frame that would allow integration
of the result in the clinical management. However, the general
trend is for these tests to become increasingly available at low
cost. If widespread genetic testing were available, for all
infants presenting with nephrotic syndrome or SRNS in the
first year of life, renal biopsy could be reserved for children
with atypical presentations such as a mixed nephritic-
nephrotic picture, hypocomplementaemia or in those in whom
no causative mutations are identified.
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